New Drugs for Alopecias

September 2019

Jacob Griggs, Rodrigo Pirmez, Antonellá Tosti

androgenetic alopecia alopecia areata prostaglandin analogs bimatoprost latanoprost SM04554 finasteride JAK inhibitors tofacitinib ruxolitinib stem cell-based therapies Wnt/β-catenin signaling pathway apremilast Propecia Latisse Xalatan

From the encyclopedia

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Bimatoprost →

a synthetic prostamide used to treat eyelashes also shows promise for stimulating hair growth on scalp

Latanoprost →

glaucoma medication with hair follicle stimulant effects

Studysummary New treatments show promise for hair loss, especially JAK inhibitors for alopecia areata.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on link.springer.com →

Discuss this study in the Community →

Research cited in this study

28 / 28 results

research New Drugs Under Investigation for the Treatment of Alopecias

26 citations , January 2019 in “Expert Opinion on Investigational Drugs”

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

research Safety Concerns When Using Novel Medications to Treat Alopecia

23 citations , October 2018 in “Expert Opinion on Drug Safety”

This review discusses the safety concerns associated with new treatments for non-scarring alopecias, highlighting that while these therapies such as JAK inhibitors and oral minoxidil show efficacy in hair regrowth, their safety profiles vary significantly, requiring careful consideration of benefits and risks.

research Androgen Modulation of Wnt/β-Catenin Signaling in Androgenetic Alopecia

39 citations , March 2018 in “Archives of Dermatological Research”

This review describes the molecular interactions between androgens and Wnt/ß-catenin signaling in androgenetic alopecia but reports no new experimental or clinical findings; the authors discuss potential Wnt/ß-catenin-targeted treatments for hair growth.

An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis

130 citations , February 2018 in “Journal of Investigative Dermatology”

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

research Alopecia Areata After Dupilumab for Atopic Dermatitis

53 citations , January 2018 in “JAAD case reports”

This report describes the case of a patient who developed alopecia areata within five weeks of starting treatment for atopic dermatitis with dupilumab.

research Alopecia Areata: Overview and Insights from January 2018

290 citations , December 2017 in “Journal of The American Academy of Dermatology”

This article reviews the epidemiology, clinical evaluation, and pathogenesis of alopecia areata and highlights recent advancements, but it does not report new clinical findings.

research Lack of Efficacy of Apremilast in 9 Patients with Severe Alopecia Areata

23 citations , September 2017 in “Journal of the American Academy of Dermatology”

This article hypothesizes that apremilast, a phosphodiesterase 4 inhibitor, could be a targeted treatment for alopecia areata due to its ability to suppress interferon-gamma production, but reports no new clinical results.

research Conventional and Novel Stem Cell-Based Therapies for Androgenic Alopecia

22 citations , August 2017 in “Stem cells and cloning”

This review analyzes therapies used for androgenic alopecia, highlighting potential advances from stem cell technologies and regenerative medicine, and reports no new clinical results.

research The Changing Landscape of Alopecia Areata: The Therapeutic Paradigm

77 citations , June 2017 in “Advances in Therapy”

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

research Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata

83 citations , June 2017 in “Journal of the American Academy of Dermatology”

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

research Androgenetic Alopecia: A Review

153 citations , March 2017 in “Endocrine”

This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , January 2017 in “Journal of the American Academy of Dermatology”

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

Effects of a Novel Finasteride 0.25% Topical Solution on Scalp and Serum Dihydrotestosterone in Healthy Men with Androgenetic Alopecia

research Effects of a Novel Finasteride 0.25% Topical Solution on Scalp and Serum Dihydrotestosterone in Healthy Men with Androgenetic Alopecia

42 citations , December 2015 in “International Journal of Clinical Pharmacology and Therapeutics”

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

research Retrospective Review of Diphencyprone in the Treatment of Alopecia Areata

27 citations , December 2015 in “Clinical and Experimental Dermatology”

This study found that hair regrowth occurred in 72.2% of alopecia areata patients treated with diphencyprone, with disease extent at baseline and duration affecting outcomes.

research Therapy for Alopecia Areata in Mice by Stimulating the Hair Cycle with Parathyroid Hormone Agonists Linked to a Collagen-Binding Domain

12 citations , November 2015 in “Journal of Investigative Dermatology Symposium Proceedings”

PTH-CBD helps reduce hair loss in mice by stimulating hair growth directly.

research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth

159 citations , October 2015 in “Science Advances”

This study observed that applying JAK-STAT pathway inhibitors to mouse and human skin led to rapid hair growth by inducing the anagen phase of hair follicles.

research The PDE4 Inhibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin In Vivo

52 citations , December 2014 in “Journal of Dermatological Science”

Apremilast may help treat hair loss in alopecia areata.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research British Association of Dermatologists’ Guidelines for the Management of Alopecia Areata 2012

218 citations , April 2012 in “British Journal of Dermatology”

This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.

research Alopecia Areata: An Autoimmune Disease Causing Hair Loss

421 citations , April 2012 in “The New England Journal of Medicine”

Alopecia Areata is an autoimmune condition causing hair loss with no cure and treatments that often don't work well.

research Prostaglandin D2 Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia

205 citations , March 2012 in “Science Translational Medicine”

PGD2 stops hair growth and is higher in bald men with AGA.

research Evidence-Based Guideline for the Treatment of Androgenetic Alopecia in Women and Men

198 citations , October 2011 in “Journal der Deutschen Dermatologischen Gesellschaft”

This article discusses the development of an evidence-based guideline for treating androgenetic alopecia and reports no new research results.

A Randomized Double-Blind Placebo-Controlled Pilot Study to Assess the Efficacy of a 24-Week Topical Treatment by Latanoprost 0.1% on Hair Growth and Pigmentation in Healthy Volunteers with Androgenetic Alopecia

research A Randomized Double-Blind Placebo-Controlled Pilot Study to Assess the Efficacy of a 24-Week Topical Treatment by Latanoprost 0.1% on Hair Growth and Pigmentation in Healthy Volunteers with Androgenetic Alopecia

81 citations , August 2011 in “Journal of The American Academy of Dermatology”

In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.

research Bimatoprost in the Treatment of Eyelash Hypotrichosis

69 citations , April 2010 in “Clinical ophthalmology”

This article reviews the use of bimatoprost for eyelash hypotrichosis and reports its effectiveness in promoting eyelash growth but highlights uncertain efficacy in cases of eyelash alopecia areata.

research Prostaglandin-Induced Hair Growth

162 citations , August 2002 in “Survey of Ophthalmology”

This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.